Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA.

Estimating country-specific LTD is important to ensure an adequate supply of IgGRT and an optimal treatment for patients with PIDDs and for improving national healthcare policymaking and production planning.